Log In
Print
BCIQ
Print
Print this Print this
 

FPI-01

  Manage Alerts
Collapse Summary General Information
Company Formula Pharmaceuticals Inc.
DescriptionSynthetic multi-peptide that targets Wilm's Tumor 1 (WT-1) antigen
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat first-remission acute myelogenous leukemia (AML)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today